This study shows that hepatic zonation determines whether mutant β-catenin drives proliferation and liver cancer by forcing differentiation to a non-permissive zone 3 fate or, when reversed, enabling MAPK- and mTOR-dependent growth
0:00Welcome to Base by Base, the papercast that brings genomics to you wherever you are. Thanks for listening, and don't forget to follow and rate us in your podcast app. So today we are diving deep into a really fundamental question in cancer biology.
0:12Why doesn't every single cell with a cancer driving mutation actually become a tumor? It's a huge puzzle, right? I mean, the simple answer is that our tissues have these incredible, robust ways of protecting themselves.
0:25And nowhere is that protection, and the paradox that comes with it more confusing than in the liver. We know that these oncogenic mutations, you know, the main molecular triggers for cancer, are actually pretty common in many tissues, but they don't immediately cause disease.
0:40And in the liver, the entire organ is structured by this massive cell signaling highway, the WNT or Pickanin pathway. Right, and that pathway controls what's called zoneation. It's basically an internal map that tells all the cells where they are and what their specific job is.
0:55And here is the monumental paradox that researchers have been really struggling with for years. WNNT signaling is absolutely essential for a healthy liver cell to mature to do its job. Okay. And yet it's also one of the most prominent drivers of hepatocellular carcinoma or HCC.
1:14It's the ultimate biological catch 22. I mean, how can the exact same signal that makes a liver cell grow up and do its job also be the thing that pushes it toward cancer. Exactly. And if we can figure out what that pre-cancer cell has to hijack to break free.
1:30We might find new ways to stop liver cancer before it even gets started. And this deep dive really shows that this highly specialized geography of the liver acts as a critical protective shield that has to be actively dismantled for cancer to thrive.
1:44It's such complex work. And, you know, we really have to celebrate the collaborative research that went into this. Today, we're focusing on findings led by Alexander Raven and Owen J. Sansom from the Cancer Research UK Scotland Institute, along with colleagues from Harvard and other institutions all over the world.
1:58Their work, published in nature, it really redefines how we think about these WNT driven tumors. Okay, so let's start by mapping out the terrain. You can't understand the liver paradox without 1st understanding empatic donation.
2:13Think of the liver lobule as a tiny city block. Functionally divided along an axis that runs from the portal node to the central vein. Exactly. And this little block is split into 3 functional zones. You have zone one, the peri portal area.
2:27where the blood comes in. Then you have zone three, the pericentral area right around the central vein. And zone 2 is just that transitional bit in the middle. And WNT signaling is what creates this whole order in the 1st place.
2:38That's right. In a healthy liver, the WNT pathway is most active near that central vein in zone three, and it drops off as you move away. So the active molecule, nuclear catnin is basically penned into zone three.
2:50Almost entirely. And this really high WNT activity is what drives that final maturation step. It compartmentalizes all the gene expression. Can you give us an example, like, what's a classic zone 3 job?
3:01The textbook example is the Gene GLUL. It's involved in ammonia detoxification. So when a hepatocite in zone 3 turns on GLUL and other markers like LGR 5, it's terminally differentiated. So it's mature, it's doing its job, and it's quiet, not dividing much.
3:18Precisely. settled down. Okay, so now let's bring in the cancer. HCC frequently has mutations in the gene CTNNB one, which is the gene that encodes Oka Catnan. Right, but the researchers notice this critical pattern.
3:31The mutations you see in human HCC are almost always these specific point mutations, usually in a place called Exon 3. And that's the first major clue. It's a huge clue. Because these ASON premutations give you a moderate sort of specific level of WNT activation.
3:47They're selected for over other mutations, like ones that just delete the APC gene. Which would give you what? Massive out of control WNT signal. Catastrophically high, total overdrive. So cancer seems to prefer a dimmer switch, not just flipping the lights all the way on.
4:02That kind of goes against the idea that more oncogene always equals more cancer. It totally does. It hints that there's an upper limit. A ceiling to WNT signaling. If you push it too hard, you just force the cell into that mature non-dividing zone 3 state.
4:17So too much WNT is actually protective. In a way, yes. It drives maturity, not proliferation. And to make things even more dangerous for the patient, this big Canton mutation, it's actually pretty weak on its own in mice.
4:29The real thread is when it cooperates with another oncagine, NYC. And we see that in people. A staggering 81% of these CTNNB one mutated tumors also have extra copies of NYC. So to get that aggressive growth.
4:42WNT needs a copilot. Okay, so to figure out how this all happens, how a single mutant cell escapes its environment, the researchers use these really clever mosaic mouse models. Yeah, this part is brilliant.
4:54They sporadically activated the CT MB1 and MYC genes at a very low density. So you just get these rare scattered mutant cells. Which lets you watch the very beginning of the story. Exactly. You can see which cells manage to grow and which ones just fizzle out.
5:06And to compare the successful souls to their neighbors that failed, they needed some really advanced tools. Oh, yeah. This is where the methodology gets really powerful. They used spatial transcriptomics.
5:17Which is like having a microscope that can also read the genetic fingerprint of every cell at C's, right? Perfect analogy. It let them compare the gene expression of tiny little precancerous lesions. We're talking clusters of just 5 or more cells right next to this single dormant mutant cells.
5:34It answers the question. What's different right here that let this one grow? But they went even deeper than just which genes were on. They used ribosome profiling. Which is a functional test. It doesn't just tell you what instructions the cell has.
5:47It tells you which instructions are actively being fed into the protein factories, the ribosomes right now. The oncogenic translate tone. Yes, it's a snapshot of what the cell is actually building. It's the difference between having a blueprint and actually running the assembly line.
6:01And then they confirmed everything with functional tests. Using drugs like repamycin, which blocks a major growth regulator called MTOR. They didn't just find correlations. They proved cause and effect.
6:13Okay, so let's get to the core discovery, the big insight. The highly differentiated zone 3 acts as an ultimate tumor suppressor. That's the headline. When they tracked those CTNNB1, MYC mutant cells, they found that the zone 3 hepatisites, the ones with those GLUL plus and LGR 5 plus markers, were almost completely refractory to becoming tumors.
6:35They were safe. Their mature differentiated state is like a powerful break on cell division, and it's a direct consequence of that really high WNT signal. So if differentiation is the shield, then the cancer cell's 1st mission has to be escaping it.
6:51This is where it all comes together, that just right WNT signal is a survival strategy. What did they see in the cells that actually started to grow? They saw that the successful mutant souls, the ones that progressed into little lesions, were characterized by a significantly reduced WNT pathway activation, lower nuclear catenin.
7:09Wait, hold on. Let me sure I'm getting this. The cells that failed to become tumors had more of the oncogenic WNT signal. While the cells that actually started a tumor had to dial the WNT signal down. Precisely.
7:20They are deliberately dampening that differentiating signal. Just enough to avoid that protective zone 3 fate. The mutation gives them a growth advantage for sure, but they have to stop it from pushing them over the cliff into maturity.
7:33So they're literally running away from the protective high WNT zone 3 identity. Where do they go? What do they use for growth instead? That's what they found. By shedding that high WNT identity. They switched on pathways linked to active MAPK signaling a major proliferation switch, and that massive protein synthesis program, the oncogenic translate home.
7:54And they weren't inventing a new way to grow, were they? They were hijacking something that was already there. Exactly. They were co-opting the exact same molecular axis that's used for normal everyday growth in the mid-lobule in zone two.
8:05The IGFBP 2 MTOR cycling D1 access. And MTR is that master regulator of cell growth you mentioned. It's like the central gas pedal. It is, and they showed that IGFBP 2, which helps control this whole process, was way upregulated in both their mouse tumors and in human HCC samples with the same WNTMYC mutations.
8:25It's the new vulnerability. So the BCat and ammutation unlocks the door, but it's the NYC copilot, and hijacking this IGFBP 2 MTOR engine that actually lets them hit the gas. Yes. And the MAPK signaling pathway is what helps them tear down the shield.
8:40They prove this using beer MV600E, which is a really powerful MATK activator. So if you combine that BRF mutation with the WNT mutation, specifically in those normally safe zone 3 cells, what happens? Rapid and dramatic tumor genesis.
8:56The MAKK activation was like an escape hatch. It just switched the cell's identity away from the protective zone 3 markers like GLUL, and forced it toward proliferative markers you'd see in zone one or two.
9:06So MADK is actively dismantling the liver's architecture. It is. And the ribosome profiling timeline backs us all up perfectly. At day four, the CTNB1 MYC combo drives this huge burst of protein synthesis for division.
9:19But by day 10, that whole program is shut down as the cells mature into their zone 3 fate. So the successful cancer cells are the ones that divide before that 10 day deadline hits. They have to escape before they get locked down.
9:30That's why the just right WNT signal from those X on 3 mutations is so critical. It's just enough to start the process, but not so much that they commit suicide by maturing too quickly. This is a huge shift in thinking.
9:42And it offers real hope for treatment, because WNA itself is famously very difficult to target with drugs. Exactly. But now we know the vulnerabilities that the tumor relies on after the WNT mutation. We're not just looking at the starting gun anymore.
9:57And what did the drug tests show? Targeting those downstream pathways. It is profound. Briefly inhibiting MTOR with rapamycin resulted in a huge reduction in tumor number and extended survival in the mice.
10:08You're hitting the gas pedal that the cancer cell hijacked. And what about the MPK pathway? Could they target that too? Yep. In the tumors driven by the WNT and BRF combination, inhibiting BRAF with a drug called Dabrafenib, successfully suppressed tumor growth.
10:23It confirms that you can either interrupt the identity switch or you can interrupt the proliferative engine, both are viable strategies. So this research really opens up a new highly druggable target space, maybe for stopping early liver cancer or even for prevention and high risk patients.
10:38Absolutely. It moves the focus away from just the mutation itself and towards the entire environmental context that allows that mutation to actually cause a problem. Okay, so what's the big take-home message here?
10:48For our overall understanding of cancer. What does this all mean? At the end of the day, it means liver zoneation acts as this incredibly powerful physical barrier against WNT driven cancer. And for a cell with a beaten mutation to progress, it has to pull off a great escape.
11:03It has to. It must dampen that differentiating WNT signal to avoid the zone 3 fate, and at the same time, co-opt the zone 2 specific IGFBP 2 MTOR growth pathway. That's what lets it fire up the machinery to divide before the liver's protective architecture forces it into retirement.
11:21Which raises a really important question for all of us to think about. What does this insight that tumor cells co-op these localized homeostatic growth mechanisms to evade their specialized job? What does that mean for how we understand cancer starting in other structured organs, like the gup or the kidney?
11:38This episode was based on an open access article under the CCBY 4.0 license. You could find a direct link to the paper and the license in our episode description. If you enjoy this, follow or subscribe in your podcast app and leave a 5 star rating.
11:53If you'd like to support our work, use the donation link in the description. Now stay with us for an original track created, especially for this episode, and inspired by the article you've just heard about.
12:02Thanks for listening, and join us next time as we explore more science. base by base.
